Clinical neuropharmacology
-
Clin Neuropharmacol · Sep 2007
Multicenter StudyOvernight switch from oral dopaminergic agonists to transdermal rotigotine patch in subjects with Parkinson disease.
To assess safety, tolerability, and efficacy outcomes of an overnight switch from oral ropinirole, pramipexole, or cabergoline to rotigotine, a dopaminergic agonist with transdermal delivery over 24 hours in subjects with established Parkinson disease (PD). ⋯ Subjects and clinicians found the overnight switch to rotigotine convenient, well tolerated, and effective for control of PD signs and symptoms for subjects previously receiving low-to-moderate doses of oral dopaminergic agonists.